Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

ctDNA detection by personalised assays in early-stage NSCLC

View ORCID ProfileKatrin Heider, View ORCID ProfileJonathan C. M. Wan, Davina Gale, Andrea Ruiz-Valdepenas, View ORCID ProfileFlorent Mouliere, James Morris, Nagmi R. Qureshi, View ORCID ProfileWendi Qian, Helena Knock, View ORCID ProfileJerome Wulff, Karen Howarth, Emma Green, Jenny Castedo, Viona Rundell, Wendy N. Cooper, Tim Eisen, Christopher G. Smith, Charles Massie, David Gilligan, Susan V. Harden, Doris M. Rassl, Robert C. Rintoul, Nitzan Rosenfeld
doi: https://doi.org/10.1101/2021.06.01.21258171
Katrin Heider
1Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
2Cancer Research UK Cambridge Centre – Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Katrin Heider
Jonathan C. M. Wan
1Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
2Cancer Research UK Cambridge Centre – Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jonathan C. M. Wan
Davina Gale
1Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
2Cancer Research UK Cambridge Centre – Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Ruiz-Valdepenas
1Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
2Cancer Research UK Cambridge Centre – Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florent Mouliere
1Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
2Cancer Research UK Cambridge Centre – Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
3Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pathology, Cancer Center Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Florent Mouliere
James Morris
1Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
2Cancer Research UK Cambridge Centre – Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nagmi R. Qureshi
4Royal Papworth Hospital NHS Foundation Trust, Cambridge CB2 0AY, UK
2Cancer Research UK Cambridge Centre – Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendi Qian
5Cambridge Clinical Trials Unit, University of Cambridge School of Clinical Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wendi Qian
Helena Knock
6Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerome Wulff
6Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jerome Wulff
Karen Howarth
7Inivata Ltd, Glenn Berge Building, Babraham Research Campus, Cambridge CB22 3FH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma Green
7Inivata Ltd, Glenn Berge Building, Babraham Research Campus, Cambridge CB22 3FH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenny Castedo
4Royal Papworth Hospital NHS Foundation Trust, Cambridge CB2 0AY, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viona Rundell
6Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy N. Cooper
1Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
2Cancer Research UK Cambridge Centre – Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Eisen
8Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
9Department of Oncology, University of Cambridge Hutchison–MRC Research Centre, Box 197, Cambridge, Biomedical Campus, Cambridge CB2 0XZ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher G. Smith
1Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
2Cancer Research UK Cambridge Centre – Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Massie
1Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
2Cancer Research UK Cambridge Centre – Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
9Department of Oncology, University of Cambridge Hutchison–MRC Research Centre, Box 197, Cambridge, Biomedical Campus, Cambridge CB2 0XZ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Gilligan
4Royal Papworth Hospital NHS Foundation Trust, Cambridge CB2 0AY, UK
8Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan V. Harden
8Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doris M. Rassl
4Royal Papworth Hospital NHS Foundation Trust, Cambridge CB2 0AY, UK
2Cancer Research UK Cambridge Centre – Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert C. Rintoul
9Department of Oncology, University of Cambridge Hutchison–MRC Research Centre, Box 197, Cambridge, Biomedical Campus, Cambridge CB2 0XZ, UK
4Royal Papworth Hospital NHS Foundation Trust, Cambridge CB2 0AY, UK
2Cancer Research UK Cambridge Centre – Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nitzan Rosenfeld
1Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
2Cancer Research UK Cambridge Centre – Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE
7Inivata Ltd, Glenn Berge Building, Babraham Research Campus, Cambridge CB22 3FH, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nitzan.rosenfeld@cruk.cam.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Blood-based assays have shown increasing ability to detect circulating tumour DNA (ctDNA) in patients with early-stage cancer. However, detection of ctDNA in patients with non-small cell lung cancer (NSCLC) has continued to prove challenging. We performed retrospective analysis to quantify ctDNA levels in a cohort of 100 patients with early-stage NSCLC prior to treatment with curative intent enrolled in the LUCID study (NCT04153526). Where tumour tissue was available for whole exome sequencing, mutations identified were used to define patient-specific sequencing assays. For those 90 patients, plasma cell-free DNA was sequenced to high depth across capture panels targeting a median of 328 mutations specific to each patient. Data was analysed using Integration of Variant Reads (INVAR), detecting ctDNA in 66.7% of patients, including 52.7% (29 of 55) patients with stage I disease and >88% detection for patients with stage II and III disease (16/18 and 15/17). ctDNA was detected in plasma at fractional concentrations as low as 9.1×10−6, and in patients with tumour volumes as low as 0.23 cm3. A 36-gene sequencing panel (InVisionFirst-Lung™) was used to analyse plasma DNA in 27 samples including the 10 cases without tumour exome data, and detected ctDNA in 59% of samples tested (16 of 27). Across the entire cohort, detection rates were higher in squamous cell carcinoma patients compared to adenocarcinoma patients (81% vs. 59%). Detection of ctDNA prior to treatment was associated with significantly shorter time free from relapse, across all patients and in patient subgroups, with Hazard Ratios >11 for selected patient subsets. Our analysis indicates that for patients with stage I NSCLC, the median ctDNA fraction in plasma is approx. 12 parts per million (0.0012%). This indicates the limits of detection that would be required for ctDNA-based liquid biopsies to detect ctDNA in the majority of patients with early-stage NSCLC.

Competing Interest Statement

K. Heider, J.C.M.W., F.M., C.G.S., C.M., and N.R. are inventors of the patent `Improvements in variant detection` (WO2019170773A1), filed by Cancer Research UK. N.R. and D. Gale are co-founders, and N.R., D. Gale, K. Howarth, and E.G. are present/former officers/consultants and/or shareholders of Inivata Ltd. Inivata provided analysis of samples by the InVisionFirst(R)-Lung assay, and all authors including Inivata-affiliated co-authors reviewed and approved the manuscript. Inivata had no role in the conceptualization or design of the clinical study, statistical analysis or decision to publish the manuscript. T.E. owns shares in and is former or present employee of AstraZeneca and Roche; T.E. received research support from AstraZeneca, Pfizer, Bayer. All other authors declare that they have no competing interests.

Clinical Trial

NCT04153526

Funding Statement

We would like to acknowledge the support of The University of Cambridge, Cancer Research UK (grant numbers A20240 and A29580) and the European Research Council under the European Union`s Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement n.337905. CtDNA isolation was performed by the Cancer Molecular Diagnostics Laboratory, which is supported by Cambridge NIHR Biomedical Research Centre, Cambridge Cancer Centre and the Mark Foundation of Cancer Research. This research was supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014) and the Cambridge Clinical Trials Unit (CCTU). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the NRES Committee West Midlands - Coventry & Warwickshire under REC number 14/WM/1072.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵† R.C.R. and N.R. jointly supervised this work

Data Availability

Data is available at the following EGA accession number: EGAS00001005246.

https://ega-archive.org/studies

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 03, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
ctDNA detection by personalised assays in early-stage NSCLC
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
ctDNA detection by personalised assays in early-stage NSCLC
Katrin Heider, Jonathan C. M. Wan, Davina Gale, Andrea Ruiz-Valdepenas, Florent Mouliere, James Morris, Nagmi R. Qureshi, Wendi Qian, Helena Knock, Jerome Wulff, Karen Howarth, Emma Green, Jenny Castedo, Viona Rundell, Wendy N. Cooper, Tim Eisen, Christopher G. Smith, Charles Massie, David Gilligan, Susan V. Harden, Doris M. Rassl, Robert C. Rintoul, Nitzan Rosenfeld
medRxiv 2021.06.01.21258171; doi: https://doi.org/10.1101/2021.06.01.21258171
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
ctDNA detection by personalised assays in early-stage NSCLC
Katrin Heider, Jonathan C. M. Wan, Davina Gale, Andrea Ruiz-Valdepenas, Florent Mouliere, James Morris, Nagmi R. Qureshi, Wendi Qian, Helena Knock, Jerome Wulff, Karen Howarth, Emma Green, Jenny Castedo, Viona Rundell, Wendy N. Cooper, Tim Eisen, Christopher G. Smith, Charles Massie, David Gilligan, Susan V. Harden, Doris M. Rassl, Robert C. Rintoul, Nitzan Rosenfeld
medRxiv 2021.06.01.21258171; doi: https://doi.org/10.1101/2021.06.01.21258171

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1101)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9785)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2319)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1563)
  • Health Policy (737)
  • Health Systems and Quality Improvement (606)
  • Hematology (238)
  • HIV/AIDS (507)
  • Infectious Diseases (except HIV/AIDS) (11657)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2149)
  • Nursing (134)
  • Nutrition (338)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1183)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (220)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (313)
  • Pediatrics (698)
  • Pharmacology and Therapeutics (302)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2188)
  • Public and Global Health (4674)
  • Radiology and Imaging (781)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)